Stroke brain-bleed deaths predicted to increase by 40% in the UK
In Europe, stroke-related brain-bleed deaths are expected to increase by 8.9% by 2050
Read Moreby Jen Brogan | Feb 15, 2024 | News | 0
In Europe, stroke-related brain-bleed deaths are expected to increase by 8.9% by 2050
Read Moreby John Pinching | Sep 29, 2023 | News | 0
FlyPharma Europe is an event for the pharma logistics industry, connecting professionals from across the globe
Read Moreby John Pinching | Jul 4, 2022 | News | 0
The deal will give Advanz an increased presence in the treatment of rare diseases
Read Moreby Anna Smith | Mar 27, 2020 | News | 0
There are about six million people in Europe with epilepsy, and approximately 40% of adults with focal-onset seizures continue to experience seizures.
Read Moreby Anna Smith | Mar 5, 2020 | News | 0
The drug is a first-of-its kind injectable RNAi therapeutic.
Read Moreby Anna Smith | Feb 19, 2020 | News | 0
The decision was based on results from the Phase III ATTR-ACT study.
Read Moreby Anna Smith | Jan 22, 2020 | News | 0
The European Commission has accepted the drug to improve wakefulness and reduce excessive daytime sleepiness in the disorders.
Read Moreby Anna Smith | Aug 22, 2019 | News | 0
Novo Nordisk submitted label updates in March this year.
Read Moreby Anna Smith | Aug 5, 2019 | News | 0
The decision comes from positive cardiovascular outcomes and renal data from the Phase III DECLARE-TIMI 58 trial.
Read Moreby Anna Smith | Jun 24, 2019 | News | 0
The indication is for patients with inherited BRCA-mutated locally advanced or metatastatic breast cancer.
Read Moreby Anna Smith | May 21, 2019 | News | 0
Astral Health will act as a gateway to the European cannabis market.
Read Moreby Anna Smith | Apr 15, 2019 | News | 0
The division will combine the Healthcare Communications team in the UK with the US Axiom team.
Read MorePharmaTimes Media Ltd.
Mansard House
Church Road
Little Bookham
Leatherhead
Surrey KT23 3JG
E: editorial@pharmatimes.com
E: subscriptions@pharmatimes.com
T: +44 (0)20 7240 6999
F: +44 (0)20 7240 4479